Zymeworks (ZYME) Financials: History & Chart

Zymeworks Inc.(ZYME)

Biotechnology · Middletown, DE

$25.65-0.56 (-2.14%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Zymeworks Inc.

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

Middletown, DE

231 employees

www.zymeworks.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Kenneth H. Galbraith

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	37.13M	4.59M	2.41M	2.52M	27.61M	48.73M	27.11M	31.03M	16.00M
Cost of Goods Sold	4.54M	0.00	2.85M	1.69M	0.00	0.00	0.00	0.00	0.00
Gross Profit	32.59M	4.59M	-439K	824K	27.61M	48.73M	27.11M	31.03M	16.00M
Gross Profit Margin	87.8%	100.0%	-18.2%	32.8%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	188.15M	46.77M	46.68M	44.98M	49.72M	49.40M	52.72M	53.25M	50.20M
Research & Development	2.51B	32.02M	2.41B	31.23M	35.58M	34.45M	35.74M	37.06M	36.35M
Selling, General & Administrative	15.12B	19.34M	15.07B	13.74M	14.10M	14.90M	17.00M	16.20M	13.90M
Operating Income (EBIT)	-155.56M	-42.18M	-47.12M	-44.15M	-22.11M	-674K	-25.61M	-22.22M	-34.20M
Operating Margin	-419.0%	-919.0%	-1956.7%	-1755.5%	-80.1%	-1.4%	-94.5%	-71.6%	-213.8%
Income Before Tax (EBT)	-151.39M	-45.29M	-46.35M	-41.48M	-18.27M	2.13M	-22.14M	-17.79M	-29.62M
Interest Income	12.50M	3.29M	2.71M	2.98M	3.53M	3.43M	3.42M	4.08M	4.79M
Interest Expense	2.07M	N/A	2.07M	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	4.17M	-3.11M	765K	2.67M	3.84M	2.81M	3.47M	4.43M	4.58M
Net Income	-149.99M	-45.02M	-44.16M	-41.21M	-19.60M	2.32M	-22.64M	-23.51M	-29.85M
Income Tax Expense	-1.40M	-273K	-2.19M	-270K	1.34M	-186K	496K	5.71M	226K
Net Profit Margin	-404.0%	-980.8%	-1834.0%	-1638.5%	-71.0%	4.8%	-83.5%	-75.8%	-186.6%
EBITDA	-146.17M	-39.91M	-44.27M	-42.46M	-19.53M	2.54M	-22.31M	-18.53M	-31.54M
EBITDA Margin	-393.7%	-869.5%	-1838.5%	-1688.3%	-70.7%	5.2%	-82.3%	-59.7%	-197.1%
Depreciation & Amortization	9.39M	2.27M	2.85M	1.69M	2.58M	3.21M	3.31M	3.69M	2.66M
EPS Basic	-2.02	-0.62	-0.59	-0.55	-0.26	0.03	-0.30	-0.31	-0.39
EPS Diluted	-2.02	-0.62	-0.59	-0.55	-0.26	0.03	-0.30	-0.31	-0.39
Weighted Average Basic Shares	72.99M	72.99M	74.67M	75.34M	75.77M	75.34M	75.17M	75.85M	76.13M
Weighted Average Diluted Shares	72.99M	72.99M	74.69M	75.34M	75.78M	77.38M	75.23M	75.88M	76.16M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	105.97M	76.30M	76.01M	412.48M	26.68M	38.95M	29.54M	53.02M
Cost of Goods Sold	0.00	0.00	142.99M	0.00	0.00	170.90M	117.10M	56.93M
Gross Profit	105.97M	76.30M	-66.98M	412.48M	26.68M	-131.94M	-87.55M	-3.91M
Gross Profit Margin	100.0%	100.0%	-88.1%	100.0%	100.0%	-338.7%	-296.3%	-7.4%
Total Operating Expenses	198.50M	213.41M	71.08M	281.95M	242.31M	55.52M	63.75M	86.15M
Research & Development	137.00M	134.62M	143.62M	208.60M	199.75M	171.34M	118.25M	56.68M
Selling, General & Administrative	61.50M	61.50M	70.40M	73.40M	42.60M	55.17M	62.88M	29.46M
Operating Income (EBIT)	-92.53M	-137.11M	-138.05M	130.53M	-215.63M	-187.47M	-151.30M	-33.13M
Operating Margin	-87.3%	-179.7%	-181.6%	31.6%	-808.2%	-481.3%	-512.1%	-62.5%
Income Before Tax (EBT)	-79.75M	-116.61M	-119.24M	135.23M	-212.36M	-180.12M	-144.85M	-34.38M
Interest Income	13.35M	19.94M	19.70M	3.60M	1.97M	5.70M	5.88M	2.64M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	166K
Other Income/Expense	12.78M	20.50M	18.81M	4.71M	3.27M	7.34M	6.45M	-1.02M
Net Income	-81.13M	-122.69M	-118.67M	124.34M	-211.84M	-180.55M	-145.44M	-36.56M
Income Tax Expense	1.38M	6.08M	-568K	10.89M	-516K	429K	582K	2.17M
Net Profit Margin	-76.6%	-160.8%	-156.1%	30.1%	-794.0%	-463.5%	-492.3%	-68.9%
EBITDA	-81.42M	-125.92M	-120.75M	142.53M	-206.05M	-184.11M	-148.99M	-29.50M
EBITDA Margin	-76.8%	-165.0%	-158.9%	34.6%	-772.3%	-472.7%	-504.3%	-55.6%
Depreciation & Amortization	11.11M	11.19M	17.30M	12.00M	9.58M	3.35M	2.31M	3.63M
EPS Basic	-1.08	-1.62	-1.72	1.91	-4.06	-3.58	-3.83	-1.26
EPS Diluted	-1.08	-1.62	-1.72	1.90	-4.61	-3.58	-3.83	-1.26
Weighted Average Basic Shares	75.34M	75.85M	68.86M	65.19M	52.13M	50.38M	37.97M	29.01M
Weighted Average Diluted Shares	75.34M	75.88M	68.86M	65.25M	52.13M	50.38M	38.02M	29.09M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.